Compare Amcor PLC (AMCR) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Amphastar Pharmaceuticals Inc — how do they compare? Amcor PLC trades at $46.93 (market cap $21.78B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Amcor PLC is far larger — about 25.2× Amphastar Pharmaceuticals Inc's market cap, and Amcor PLC pays a 5.52% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMCR | AMPH | |
|---|---|---|
Market Cap | $21.78B | $863.95M |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $30.81 |
52-Week Low | $36.69 | $16.87 |
Enterprise Value | $36.90B | $1.26B |
Dividend Yield | 5.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.86, up 1.7% today, near the consensus price target of $47.00. The stock shows bullish technical signals from moving averages, with RSI indicating mild overbought conditions. Recent quarters saw earnings beats, with Q2 2026 EPS expected at $1.19. Revenue grew to $15.01B in 2025, though net income margin declined to 3.06%. The company expanded its packaging facility in China and partnered with Kelpi for sustainable solutions, signaling growth initiatives.
Outlook is cautiously optimistic with analyst consensus at Buy (64%), but risks include margin pressure and high P/E of 38.44. Investment appeal hinges on earnings delivery and cost management amid competitive and macroeconomic headwinds.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
